Phase I Trial: Sponsor code: X11-201-00001

Submission date	Recruitment status	Prospectively registered
28/03/2025	Recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
31/03/2025	Deferred	☐ Results
Last Edited	Condition category	Individual participant data
31/03/2025	Other	[X] Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Ashley Brooks

Contact details

MAC Clinical Research , Early Phase Suite Neuroscience Centre of Excellence Citilabs 1.0, Nelson Street Manchester United Kingdom M13, 9NQ

+44 (0) 161 274 1603

ashleybrooks@macplc.com

Type(s)

Public, Scientific

Contact name

Dr Neel Bhatt

Contact details

MAC Clinical Research Centre 11 Tiger Court King's Drive King's Business Park Prescot Merseyside United Kingdom L34 1BH +44 (0) 151 482 4700 neelbhatt@macplc.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

1009721

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Sponsor code: X11-201-00001

Study information

Scientific Title

Phase I Trial: Sponsor code: X11-201-00001

Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 11/03/2025, Wales Research Ethics Committee 1 Cardiff (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 2922940912; wales.rec1@wales.nhs.uk), ref: 25/WA/0026

Study design

Phase 1a/b Randomized double blinded placebo controlled study

Primary study design

Interventional

Study type(s)

Other, Treatment

Health condition(s) or problem(s) studied

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s))

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

10/06/2026

Eligibility

Key inclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Other

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment 27/03/2025

Date of final enrolment 11/06/2026

Locations

Countries of recruitmentUnited Kingdom

Study participating centre
MAC Clinical Research, Early Phase Unit
Neuroscience Centre of Excellence Citilabs1.0, Nelson Street
Manchester, Greater Manchester
United Kingdom
M13 9NQ

Study participating centre
MAC Clinical Research Centre
11 Tiger Court, King's Drive King's Business Park
Prescot, Merseyside
United Kingdom
L34 1BH

Sponsor information

Organisation

Otsuka Pharmaceutical Development & Commercialization, Inc.

Funder(s)

Funder type Industry

Funder Name

Otsuka Pharmaceutical Development & Commercialization, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes